Genmab A/S (ETR:GE9)

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of EUR 14.90 billion. The enterprise value is 12.56 billion.

Market Cap	14.90B
Enterprise Value	12.56B

Important Dates

The next estimated earnings date is Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.55M
Shares Outstanding	n/a
Shares Change (YoY)	-3.37%
Shares Change (QoQ)	-3.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.84M

Valuation Ratios

The trailing PE ratio is 12.77 and the forward PE ratio is 15.65.

PE Ratio	12.77
Forward PE	15.65
PS Ratio	4.80
PB Ratio	3.30
P/TBV Ratio	5.48
P/FCF Ratio	16.04
P/OCF Ratio	15.43
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.98, with an EV/FCF ratio of 13.52.

EV / Earnings	10.76
EV / Sales	4.05
EV / EBITDA	10.98
EV / EBIT	11.59
EV / FCF	13.52

Financial Position

The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.03.

Current Ratio	6.22
Quick Ratio	6.20
Debt / Equity	0.03
Debt / EBITDA	0.11
Debt / FCF	0.14
Interest Coverage	49.22

Financial Efficiency

Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 15.86%.

Return on Equity (ROE)	28.12%
Return on Assets (ROA)	13.26%
Return on Invested Capital (ROIC)	15.86%
Return on Capital Employed (ROCE)	21.84%
Revenue Per Employee	1.18M
Profits Per Employee	442,334
Employee Count	2,682
Asset Turnover	0.61
Inventory Turnover	21.91

Taxes

In the past 12 months, Genmab has paid 155.66 million in taxes.

Income Tax	155.66M
Effective Tax Rate	11.77%

Stock Price Statistics

The stock price has decreased by -28.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-28.43%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	28.57
Average Volume (20 Days)	29

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of EUR 3.11 billion and earned 1.17 billion in profits. Earnings per share was 18.41.

Revenue	3.11B
Gross Profit	2.94B
Operating Income	1.09B
Pretax Income	1.32B
Net Income	1.17B
EBITDA	1.13B
EBIT	1.09B
Earnings Per Share (EPS)	18.41

Balance Sheet

The company has 2.47 billion in cash and 126.02 million in debt, giving a net cash position of 2.34 billion.

Cash & Cash Equivalents	2.47B
Total Debt	126.02M
Net Cash	2.34B
Net Cash Per Share	n/a
Equity (Book Value)	4.51B
Book Value Per Share	73.41
Working Capital	2.79B

Cash Flow

In the last 12 months, operating cash flow was 965.95 million and capital expenditures -36.99 million, giving a free cash flow of 928.96 million.

Operating Cash Flow	965.95M
Capital Expenditures	-36.99M
Free Cash Flow	928.96M
FCF Per Share	n/a

Margins

Gross margin is 94.54%, with operating and profit margins of 34.95% and 37.59%.

Gross Margin	94.54%
Operating Margin	34.95%
Pretax Margin	42.60%
Profit Margin	37.59%
EBITDA Margin	36.40%
EBIT Margin	34.95%
FCF Margin	29.91%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.37%
Shareholder Yield	n/a
Earnings Yield	7.83%
FCF Yield	6.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.99 and a Piotroski F-Score of 5.

Altman Z-Score	9.99
Piotroski F-Score	5